Ligands of Immunopharmacology

AhR agonist 2 (Compound 12a) is a potent agonist of aryl hydrocarbon receptor ( AhR ) with an EC 50 of 0.03 nM. AhR agonist 2 induces rapid nuclear enrichment of AhR, triggers the transcription of downstream genes and promote skin barrier repair.

AhR agonist 2 (Compound 12a) is a potent agonist of aryl hydrocarbon receptor ( AhR ) with an EC 50 of 0.03 nM. AhR agonist 2 induces rapid nuclear enrichment of AhR, triggers the transcription of downstream genes and promote skin barrier repair.

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.Form:Solid

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.Form:Solid

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.Form:Solid

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.Form:Solid

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.Form:Solid

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC 50 s of 0.885 and 2.03 nM for human and mouse AhR.

AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC 50 of &lt 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint

AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC 50 of &lt 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint

AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC 50 of &lt 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint

AM 103 is a potent and selective FLAP inhibitor, with an IC 50 value of 4.2 nM.In VitroAM 103 has an IC 50 value of 349 nM in the human blood LTB4 inhibition assay. AM 103 has an excellent CYP profile against the 5 most common CYP isoforms with IC